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Abstract We report a case of intoxication by the synthetic
cannabinoid MAM-2201 ([1-(5-fluoropentyl)-1H-indol-3-yl]
(4-methyl-1-naphthalenyl)-methanone). A 31-year-old man
smoked about 300 mg of a herbal blend. He experienced an
acute transient psychotic state with agitation, aggression,
anxiety, and vomiting associated with a sympathomimetic
syndrome. MAM-2201 was detected and quantified in a
plasma sample using liquid chromatography-tandem mass
spectrometry (LC–MS–MS). The level was 49 ng/ml 1 h
after smoking. The use of other drugs was analytically
excluded. The presence of MAM-2201 was confirmed in
the herbal blend using gas chromatography–mass spec-
trometry (GC–MS) and LC–high resolution MS. This is the
first description of an analytically confirmed intoxication
and of the determination of MAM-2201 in human blood
plasma.
Keywords Synthetic cannabinoids  MAM-2201 
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Introduction
Cannabis is the most widely produced and consumed illicit
substance worldwide [1]. The psychoactive effects of can-
nabis are mainly due to D9-tetrahydrocannabinol (D9-THC),
which acts as a partial agonist on CB1 and CB2 cannabinoid
receptors [2]. Since the isolation of D9-THC in 1964, hun-
dreds of cannabinoids have been synthesized for biomedical
research purposes with the aim of finding new therapeutic
agents [2, 3]. More recently, these synthetic cannabinoids
have attracted the interest of recreational drug users [4].
Around 2004, herbal and plant mixtures (‘‘spices’’) emerged
as legal alternatives to cannabis in Europe [3]. It was initially
assumed that the cannabis-like effects were derived from the
plants themselves. However, the suspicion was raised that
synthetic compounds added to the herbal blends were the
main causes of the pharmacological activities [4, 5]. In 2008,
the synthetic cannabinoids JWH-018 and CP47,497 were
identified for the first time in ‘‘Spice’’, one of the first com-
mercialized examples of ‘‘herbal incense’’ [6–8]. Since then
numerous synthetic cannabinoids have been identified in
other herbal and plant mixtures [6, 9–18]. Spice drugs have
become popular alternatives to marijuana [19] and an
important new class of designer drugs [4, 20, 21].
Here, we present a case of intoxication with the synthetic
cannabinoid MAM-2201 ([1-(5-fluoropentyl)-1H-indol-3-yl]
(4-methyl-1-naphthalenyl)-methanone, CAS 1354631-24-5,
Fig. 1) [14, 15, 22], and describe the analytical documentation
of MAM-2201 in both herbal blends and blood plasma of the
patient. To our knowledge, this is the first described case of an
analytically confirmed intoxication with MAM-2201.
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Case history
A 31-year-old man of Japanese descent smoked a hookah
(water pipe) with about 300 mg of ‘‘Samurai King’’, one of
two herbal incenses that he had purchased via the Internet
(Fig. 2). After a few minutes, he felt increasingly uncom-
fortable, began to shiver, and vomited several times.
Because he became more and more confused and aggres-
sive, his wife alerted the emergency medical services.
Thirty minutes after smoking the herbs, paramedics met a
highly agitated and confused patient. His pupils were
dilated and hardly reacted to light. The Glasgow coma
scale score was 13, the pulse rate 144 /min, and blood
pressure 160/100 mmHg. The capillary blood glucose was
8.6 mmol/l. During transport to the emergency department,
the patient vomited again. At the emergency department,
the patient was still agitated and in a state of panic. The
patient could not be examined further and had to be iso-
lated. The pulse rate was 120 /min, the blood pressure
136/77 mmHg, respiratory rate 24 /min, and ear body
temperature 36.9 C. Laboratory studies indicated slight
hypokalemia at 3.2 mmol/l (normal 3.7–4.7 mmol/l), ele-
vated aspartate alanine transferase at 50 U/l (normal
10–37 U/l), hyperglycemia at 9.5 mmol/l (normal 3.8–6.1
mmol/l), hypocalcemia at 2.06 mmol/l (normal 2.10–2.65
mmol/l), and hypophosphatemia at 0.74 mmol/l (normal
0.80–1.50 mmol/l). The blood count revealed leukocytosis
of 13.66 9 109 /l (normal 3.5–10.0 9 109 /l) with lym-
phocytosis, monocytosis, eosinophilia, and basophilia, but
with a normal neutrophil count. The coagulation parame-
ters were normal. Venous blood gas analysis 1 h after
consumption of the product showed respiratory acidosis
(pH 7.26, pCO2 8.04 kPa, pO2 5.87 kPa, HCO3 26.4 mmol/l,
base excess -1.6 mmol/l, anion gap 10.6 mmol/l) with
elevated lactate at 4.5 mmol/l. After 1 h at the emergency
department and about 1.5 h after the consumption, the
psychological conditions returned to normal. On clinical
examination, the pupils were still dilated with slow
reaction to light. However, blood pressure (110/50 mmHg)
and heart rate (84 /min) had become normal. The electro-
cardiogram (ECG) 1.75 h after the consumption demon-
strated a normal sinus rhythm with a marginally prolonged
QTc interval of 440 ms. The patient was discharged 3 h
after arrival at the emergency department. An alcohol
blood test and a standard drug screening test were negative.
Two spice products (Hawaiian 2nd and Samurai King)
and a plasma sample of the patient taken approximately
1 h after consumption of the herbal blend Samurai King
were used for further toxicological analyses as described
below.
Materials and methods
Chemicals and reagents
[1-(5-Fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthale-
nyl-methanone) (MAM-2201) was obtained from Cayman
Chemical (Ann Arbor, MI, USA) and delivered by Adip-
ogen (Liestal, Switzerland). JWH-018-d11 was obtained
from Chiron (Trondheim, Norway). Water was purified with
a Purelab Ultra Millipore filtration unit from Labtech
(Wohlen, Switzerland), and acetonitrile of HPLC grade was
obtained from Sigma-Aldrich (Buchs, Switzerland). All
other chemicals (analytical grade) were from VWR (Dietikon,
Switzerland).
Sample preparations for herbal blends
A small amount of each herbal blend (Hawaiian 2nd and
Samurai King) was dissolved in 1 ml of methanol and left
at room temperature for 10 min. After centrifugation
(10,000 g, 5 min), the supernatant was transferred to an
autosampler vial and analyzed by gas chromatography-
mass spectrometry (GC–MS). An aliquot of the extract was
diluted tenfold with methanol and analyzed by liquid
Fig. 1 Chemical structures of
MAM-2201 and the related
cannabinoids AM-2201 and
JWH-122
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chromatography-high resolution MS (LC–HRMS) as descri-
bed below.
Plasma sample preparation for general drug screening
Plasma extraction was performed by liquid–liquid extrac-
tion (LLE) according to Maurer et al. [23] with slight
modifications. Briefly, 200 ll of plasma was extracted with
1000 ll of a mixture of diethyl ether/ethyl acetate (1:1;
v/v) after addition of 200 ll of phosphate buffer (500 mM,
pH 6). After phase separation by centrifugation, the organic
extract was transferred into an autosampler vial. The
aqueous residue was then basified with 100 ll of 1 M
sodium hydroxide solution and again extracted with 500 ll
of the same solvent mixture. The combined organic
extracts were evaporated at 50 C under nitrogen, dis-
solved in 50 ll of methanol, and analyzed by LC–MS–MS.
Plasma sample preparation for quantification
of synthetic cannabinoids
Plasma extraction was performed as described for the
above general drug screening with slight modifications.
Plasma (50 ll) was first mixed with 10 ll of internal
standard (IS, JWH-018-d11, 5 ng/ml), and the procedure
that followed was almost the same as described above.
GC–MS conditions
The samples were analyzed using a Thermo Fisher (Zurich,
Switzerland) GC–MS system consisting of a Trace GC
Ultra, a DSQ II mass selective detector, and an AS 3000
autosampler. The GC conditions were: injection, splitless
mode; column, 5 % phenylmethylsiloxane (ZB-5;
30 m 9 0.25 mm i.d., 250 nm film thickness); carrier gas,
helium; flow rate, 1 ml/min; column temperatures, 80 C
hold for 2 min, increased to 290 C at 30 C/min and hold
for 15 min. The MS conditions were: ionization, electron
ionization (EI) mode; source temperature, 250 C; solvent
delay, 5 min; detection, full scan mode (m/z 50–600).
LC–HRMS conditions
Analysis was performed using a Dionex UltiMate 3000
UHPLC coupled to an ABSciex 5600 TripleTOF HR mass
spectrometer with Analyst software (Version 1.6, AB
Sciex, Darmstadt, Germany). The LC settings were: col-
umn, Phenomenex (Aschaffenburg, Germany) Synergi
Polar-RP (100 9 2.0 mm i.d., particle size 2.5 lm);
mobile phase components, 25 mM ammonium acetate
buffer in water containing 0.1 % (v/v) acetic acid (A) and
acetonitrile containing 0.1 % (v/v) acetic acid (B). The
flow rate was 0.5 ml/min with the following gradient pro-
gram: 0–1 min 5 % B, 1–6 min to 20 % B, 6–10 min to
80 % B, 10–13 min to 90 % B, 13–14 min to 100 % B,
hold at 100 % B for 1 min, and at 15.01 min reequilibra-
tion to 5 % B for 2 min. The MS ionization conditions
were: interface, electrospray ionization (ESI) positive
mode; gas 1 and 2, nitrogen (50 psi); ion spray voltage,
4500 V; ion-source temperature, 300 C; curtain gas,
nitrogen (25 psi); declustering potential, 80 V. Time-of-
flight (TOF) MS conditions were: scan range, m/z 100–700;
accumulation time, 0.25 s; collision energy, 5 eV.
Enhanced product ion (EPI) scan conditions were: scan
range, m/z 100–700; accumulation time, 0.099 s; collision
energy spread, 35 ± 15 eV. Information dependent data
acquisition (IDA) settings were programmed for the first,
second, third, and fourth most intense ions, which exceeded
Fig. 2 Packaging of the herbal
smoking mixtures Hawaiian 2nd
and Samurai King
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intensities of 200 cps using dynamic background subtrac-
tion. The exclusion time was 10 s. Mass calibration of the
TOF instrument was performed by external calibration
prior to analysis.
LC–MS–MS conditions
The analysis was performed using a Dionex UltiMate 3000
HPLC system coupled to an ABSciex 5500 Qtrap linear ion
trap (LIT) quadrupole mass spectrometer (AB Sciex) with
Analyst software (Version 1.5.2). The MS conditions were:
ion source, Turbo T operated in positive ESI mode; gas 1,
nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray volt-
age, 5500 V; ion-source temperature, 450 C; curtain gas,
nitrogen (20 psi), collision gas, medium. For general drug
screening, IDA was used after multiple reaction monitoring
(MRM) with two transitions per analyte as survey scans.
EPI spectra were recorded using the following parameters:
scan rate, 10,000 Da/s; scan range, m/z 50–550; collision
energy spread, 35 ± 15 eV; profile mode. IDA settings
were programmed for the MRM transitions that exceeded
intensities of 2000 cps. The exclusion time was 4 s. EPI
spectra were processed versus an in-house library using
Analyst Software 1.5.2.
For quantification of MAM-2201, the same LC–MS–MS
conditions were applied as described above, but only MRM
transition conditions for MAM-2201 and the IS JWH-018-
d11 were as follows. For MAM-2201, MRM 1: ion transi-
tion, 374.2/169.1; declustering potential (DP), 161 V;
collision energy (CE), 37 eV; entrance potential (EP),
10 V; collision exit potential (CXP), 14 V. MRM 2: ion
transition, 374.2/115.1; DP, 161 V; CE, 99 eV; EP, 10 V;
CXP, 12 V. MRM 3: ion transition, 374.2/232.2; DP,
161 V; CE, 35 eV; EP, 10 V; CXP, 12 V. For the IS JWH-
018-d11, MRM 1: ion transition, 353.1/155.1; DP, 111 V;
CE, 35 eV; EP, 10 V; CXP, 14 V. MRM 2: ion transition,
353.1/127.1; DP, 111 V; CE, 71 eV; EP, 10 V; CXP, 14 V.
MRM 3: ion transition, 353.1/225.1; DP, 111 V; CE,
35 eV; EP, 10 V; CXP, 14 V. Quantification was per-
formed via a five-point calibration curve as described under
the method validation.
Method validation for MAM-2201 determination
A simplified method validation was performed as recom-
mended for single case analysis [24] including specificity,
matrix effects, limit of quantification, and accuracy and
precision studies.
Specificity
Six blank plasma samples from different sources were
analyzed for peaks interfering with the detection of
MAM-2201 or the IS. Two zero samples (blank sam-
ple ? IS) were analyzed to check for appropriate IS purity
and the presence of native analytes.
Calibration
Calibration was performed in duplicate at the following five
concentration levels: 0.05, 0.1, 10, 20, and 50 ng/ml. The
regression lines were calculated using weighted (1/X) least-
squares regression models to account for unequal variances
(heteroscedasticity) across the calibration range. The back-
calculated concentrations of all calibration samples were
compared to their respective nominal values and quantitative
accuracy was required within 20 % of the target.
Accuracy and precision
Six quality control (QC) samples at low (0.2 ng/ml) and high
(40 ng/ml) concentrations were analyzed. QC concentrations
were determined via the respective calibration curves.
Accuracy was calculated in terms of bias as the percent
deviation of the calculated mean concentration at each con-
centration level from the corresponding theoretical concen-
tration. Precision was calculated as relative standard
deviation (RSD).
Matrix effects
Matrix effect (ME) studies were performed at QC low and
high concentrations using six different plasma sources
according to the previous report [25].
Quantification limits
The limit of quantification (LOQ) of the method was
defined as a concentration giving the signal-to-noise ratio
of 10:1. The lowest point of the calibration curve was set to
be the LOQ concentration.
Results and discussion
Symptoms and toxicities
The present case report is the first description in the sci-
entific literature of an analytically confirmed intoxication
with the synthetic cannabinoid MAM-2201. MAM-2201
had been first identified as an ingredient of herbal smoking
blends in summer 2011 [15, 22]. It is structurally related to
the known synthetic cannabinoids AM-2201 and JWH-122
and is therefore also referred to as 40-methyl-AM-2201,
AM 2201-pMe, and 500-fluoro-JWH-122 (Fig. 1). Due to
the structural relationship to AM-2201 and JWH-122, it
Forensic Toxicol (2013) 31:164–171 167
123
can be assumed that MAM-2201 would have similar
pharmacological properties to those of the two cannabi-
noids. In fact, similar effects to those of AM-2201 have
been described by recreational users on the Internet
(http://www.drugs-forum.com, http://www.bluelight.ru,
http://www.eve-rave.ch). Of note, the used and recom-
mended doses for MAM-2201 appear to be smaller than
those of other cannabinoids, and it is reported to have
longer-lasting effects. MAM-2201 was reported to be
active at doses as low as 500 lg and to have a very steep
dose–response curve (http://www.wiki.bluelight.ru). Panic
attacks and vomiting are noted as typical symptoms at
higher doses. However, scientific clinical data on MAM-
2201 are lacking.
In our patient, psychotic symptoms and vomiting were
the predominant symptoms. Confusion, agitation, aggres-
sion, paranoid thinking, and anxiety are common
symptoms after consumption of synthetic cannabinoids
[4, 20, 26–30]. In addition, we observed sympathomimetic
effects including mydriasis and increases in blood pressure
and heart rate. Cannabis and synthetic cannabinoids
produce tachycardia and hypertension [31–36], and myo-
cardial infarction has been associated with the use of both
cannabis and synthetic cannabinoids [37]. Cannabinoids
stimulate the sympathetic nervous system to release nor-
epinephrine [34]. Similarly, mydriasis results from central
stimulation of the sympathetic efferent pathways by can-
nabinoids [38]. However, the cardiovascular effects of
cannabinoids are complex and also include sympathoinhi-
bition [39].
The effects of the synthetic cannabinoids appear to be
short-lived in contrast to those of some designer amphet-
amine derivatives that may produce sympathomimetic
toxicity for up to 72 h or longer [31, 40]. Supportive care
Fig. 3 Total ion chromatograms (a) and electron ionization mass spectra (b) of Hawaiian 2nd (left side), Samurai King (right side) and the
authentic MAM-2201 (c) recorded by gas chromatography–mass spectrometry
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(e.g., monitoring and/or hydration) and a quiet environment
seem sufficient to treat most cases of acute intoxication by
synthetic cannabinoids. Patients who present symptoms of
anxiety, panic, agitation, and arousal may benefit from the
use of benzodiazepines [31]. However, special attention is
needed for the risk of cardiovascular complications; ECG
and cardiac enzymes should be monitored to exclude
myocardial ischemia.
The hyperglycemia and increases in white cell blood
count in our patient were interpreted as a consequence of
stress. In our case, the medical information and the herbal
mixtures provided were suggestive of intoxication with any
synthetic cannabinoid. Nevertheless, because of the strong
sympathomimetic reaction, a mixed-type intoxication
could not be excluded initially.
Analysis of herbal blends
As shown in Fig. 3, GC–MS analysis of both herbal blends
revealed one major peak per product at 21.5 and 21.6 min
for Hawaiian 2nd and Samurai King, respectively. The
underlying EI mass spectra were identical in both herbal
blends as shown in Fig. 3b. Further analysis by LC–HRMS
again revealed identical compounds in both herbal blends
with exact protonated molecular ions of m/z 374.1916 and
374.1915 for Hawaiian 2nd and Samurai King, respectively.
These accurate masses correspond to a molecular formula
of C25H25FNO. A closer look at the fragment ions gave a
hint for typical fragmentation of synthetic cannabinoids of
the JWH family [41] with the major fragment at m/z
169.0652 indicating a molecular formula of C12H9O and
m/z 232.1137 indicating a molecular formula of C14H15FO
as exemplified for Samurai King in Fig. 4. In comparison
with other already known synthetic cannabinoids, these
findings suggested the presence of a methyl group at the
naphthyl moiety, similar to that of JWH-122, and a fluorine
atom in the pentyl chain as in AM-694. SciFinder search
with these suggestions gave the hint for MAM-2201. Final
comparison of retention time and mass spectra in GC–MS
and LC–HRMS versus commercially available MAM-2201
confirmed its identity for both herbal blends.
Drug screening and MAM-2201 quantification
for plasma sample from patient
Screening of the plasma sample by LC–MS–MS revealed
only the presence of MAM-2201 and caffeine. No other
drugs, such as cocaine, amphetamines, or other synthetic
cannabinoids, could be detected in the sample. Unfortu-
nately, no urine was available to perform a broader
screening analysis.
Quantification over a five-point calibration curve as
described under the method validation revealed an
MAM-2201 concentration of 49 ng/ml in the patient’s
plasma sample. A simplified method validation was per-
formed with regard to specificity, accuracy, precision,
matrix effects, and LOQ. Accuracy was 92.3 % for the low
concentration and 97.5 % for the high concentration. Pre-
cision data were 9.3 and 7.3 % for the low and high QC
samples, respectively. Matrix effects were within the
required limits with 107 % (RSD 15.6 %) and 90.0 %
(RSD 7.1 %) for low and high concentrations, respectively.
The LOQ was consistent with the lowest calibrator con-
centration with less than 20 % bias. The limit of detection
(LOD) was not systematically evaluated.
Conclusions
To our knowledge, this is the first description of the clinical
symptoms of MAM-2201 intoxication. Furthermore, this is
also the first report of identification and quantification of
MAM-2201 in a human plasma sample in an actual
intoxication case.
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